To determine the levels of angiogenic biomarkers: vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 1 (sVEGFR1 or sFlt-1), platelet count, and the VEGF/platelet ratio in preeclampsia.
Methods
Forty-four cases of preeclampsia and 44 controls were recruited.
Results
The serum VEGF, sVEGFR1, and VEGF/platelet ratio were significantly higher and platelet counts lower in preeclampsia in comparison to controls (VEGF: median = 178 vs. 97 pg/mL, p < 0.0001, sVEGFR1: 1634 vs. 627 pg/mL, p < 0.0001, VEGF/platelet ratio: 1.148 vs. 0.417, and platelet count: 178 × 103/µL vs. 232 × 103/µL, p = 0.0006). The VEGF and VEGF/platelet ratio showed better diagnostic accuracy for differentiating preeclampsia, with an area under the curve of 97.47% (95% CI: 0.95–1.00) and 89.46% (95% CI: 0.82–0.96), respectively. VEGFA: c.-2055A>C (rs699947) AA genotype exhibited higher serum VEGF levels associated with preeclampsia.
Conclusion
The higher levels of angiogenic biomarkers in preeclampsia, suggest a role in the pathogenesis and potential diagnosis.
KamraniAAlipourfardIAhmadi-KhiaviH, et al.The role of epigenetic changes in preeclampsia. Biofactors2019; 45: 712–724.
2.
WilesKChappellLCLightstoneL,et al.Updates in diagnosis and management of preeclampsia in women with CKD. Clin J Am Soc Nephrol2020; 15: 1371–1380.
3.
QuHKhalilRA. Vascular mechanisms and molecular targets in hypertensive pregnancy and preeclampsia. Am J Physiol Heart Circ Physiol2020; 319: H661–HH81.
4.
KhidriFF. Various presentations of preeclampsia at tertiary care hospital of Sindh: a cross-sectional study. Curr Hypertens Rev2020; 16: 216–222.
5.
PalmerBRPatersonMAFramptonCM, et al.Vascular endothelial growth factor-A promoter polymorphisms, circulating VEGF-A and survival in acute coronary syndromes. PLoS One2021; 16: e0254206.
6.
AhirBKEngelhardHHLakkaSS. Tumor development and angiogenesis in adult brain tumor: glioblastoma. Mol Neurobiol2020; 57: 2461–2478.
7.
TandonVHiwaleSAmleD,et al.Assessment of serum vascular endothelial growth factor levels in pregnancy-induced hypertension patients. J Pregnancy2017; 2017: 1–5.
8.
SellamiNLamineLBTurkiA, et al.Association of VEGFA variants with altered VEGF secretion and type 2 diabetes: a case-control study. Cytokine2018; 106: 29–34.
9.
RennerWKotschanSHoffmannC, et al.A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res2000; 37: 443–448.
10.
Rabbind SinghAGuptaRShuklaM, et al.Association of VEGFA promoter polymorphisms rs699947 and rs35569394 with diabetic retinopathy among North-Central Indian subjects: a case-control study. Ophthalmic Genet2022; 43: 80–87.
11.
HuangZ-YYuanY-RKongY-L, et al.Vascular endothelial growth factor-A is associated with platelets and complement 4 in patients with primary Sjögren’s syndrome. Ann Clin Lab Sci2020; 50: 790–796.
12.
SuM-TWangC-YTsaiP-Y, et al.Aspirin enhances trophoblast invasion and represses soluble fms-like tyrosine kinase 1 production: a putative mechanism for preventing preeclampsia. J Hypertens2019; 37: 2461–2469.
13.
PoweCELevineRJKarumanchiSA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation2011; 123: 2856–2869.
14.
PantVYadavBKSharmaJ. A cross sectional study to assess the sFlt-1: plGF ratio in pregnant women with and without preeclampsia. BMC Pregnancy Childbirth2019; 19: 266.
15.
HunterAAitkenheadMCaldwellC, et al.Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension2000; 36: 965–969.
16.
ACOG. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol2013; 122: 1122.
17.
KhidriFFWaryahYMAliFK, et al.MTHFR and F5 genetic variations have association with preeclampsia in Pakistani patients: a case control study. BMC Med Genet2019; 20: 1–12.
18.
ShimJHParkJWKimJH, et al.Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci2008; 99: 2037–2044.
19.
KogaHTokunagaYHisamotoT, et al.Ratio of serum vascular endothelial growth factor to platelet count correlates with disease activity in a patient with POEMS syndrome. Eur J Intern Med2002; 13: 70–74.
20.
LaiQVitaleAManziaTM, et al.Platelets and hepatocellular cancer: bridging the bench to the clinics. Cancers (Basel)2019; 11: 1568.
21.
WalleMGelawYGetuF, et al.Preeclampsia has an association with both platelet count and mean platelet volume: a systematic review and meta-analysis. PLoS One2022; 17: e0274398.
22.
WoldeamanuelGGTlayeKGWuL, et al.Platelet count in preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol MFM2023: 100979. DOI: 10.1016/j.ajogmf.2023.100979.
23.
DijmărescuALBoldeanuLRaduM, et al.The potential value of diagnostic and predictive serum biomarkers for preeclampsia. Rom J Morphol Embryol2021; 62: 981–989.
24.
KurbanovB. 77. The role of VEGF as prognostic marker of preeclampsia. Pregnancy Hypertens2018; 13: S68.
25.
AliLESalihMMElhassanEM, et al.Placental growth factor, vascular endothelial growth factor, and hypoxia-inducible factor-1α in the placentas of women with pre-eclampsia. J Matern Fetal Neonatal Med2019; 32: 2628–2632.
26.
LyallFGreerIABoswellF,et al.Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol1997; 104: 223–228.
27.
AroraPSangwanSKGuptaR, et al.Association of vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 polymorphisms with their circulating protein levels in preeclampsia. J Anat Soc India2019; 68: 215–220.
28.
TangYYeWLiuX, et al.VEGF and sFLT-1 in serum of PIH patients and effects on the foetus. Exp Ther Med2019; 17: 2123–2128.
29.
ThakurPChakravartiAAggarwalS, et al.Elevated levels of vascular endothelial growth factor in adults with severe dengue infection. Virusdisease2016; 27: 48–54.
30.
XiaoY-YLiuYZengT, et al.Plasma VEGF levels and etiology of thrombocytopenia, a biomarker study. Blood2011; 118: 4684.
31.
ShimizuYArimaKNoguchiY, et al.Vascular endothelial growth factor (VEGF) polymorphism rs3025039 and atherosclerosis among older with hypertension. Sci Rep2022; 12: 5564.
32.
BaoLSyedRAloahdMS. Analysis of VEGF gene polymorphisms and serum VEGF protein levels contribution in polycystic ovary syndrome of patients. Mol Biol Rep2019; 46: 5821–5829.
33.
Al-HabboubiHHSaterMSAlmawiAW, et al.Contribution of VEGF polymorphisms to variation in VEGF serum levels in a healthy population. Eur Cytokine Netw2011; 22: 154–158.
34.
AminuddinNASutanRMahdyZA, et al.The feasibility of soluble fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia. PLoS One2022; 17: e0265080.
35.
CaillonHTardifCDumontetE, et al.Evaluation of sFlt-1/PlGF ratio for predicting and improving clinical management of pre-eclampsia: experience in a specialized perinatal care center. Ann Lab Med2018; 38: 95–101.
36.
ThadhaniRLemoineERanaS, et al.Circulating angiogenic factor levels in hypertensive disorders of pregnancy. NEJM Evidence2022; 1: EVIDoa2200161.
37.
AgrawalSShinarSCerdeiraAS, et al.Predictive performance of PlGF (placental growth factor) for screening preeclampsia in asymptomatic women. Hypertension2019; 74: 1124–1135.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
